CellCept works by starving your immune cells of a building block they need to multiply. Specifically, it blocks an enzyme that immune cells depend on to make new DNA, which prevents them from reproducing fast enough to attack a transplanted organ or, in off-label uses, your own tissues. This makes it one of the more targeted immunosuppressants available, since it hits immune cells harder than most other cell types in your body.
The Enzyme It Blocks
CellCept (mycophenolate mofetil) is actually a prodrug, meaning it doesn’t do anything on its own. After you swallow it, your body quickly converts it into its active form, called mycophenolic acid, or MPA. MPA then blocks an enzyme called IMPDH, which cells use to produce guanosine, one of the four chemical “letters” that make up DNA.
Without enough guanosine, a cell can’t copy its DNA, and a cell that can’t copy its DNA can’t divide. Most cells in your body have a workaround: they can recycle guanosine from old, broken-down DNA using what’s called a salvage pathway. But T cells and B cells, the two main types of immune cells responsible for organ rejection, are critically dependent on making guanosine from scratch. They can’t rely on the recycling route nearly as well. This is why CellCept suppresses immune cells more powerfully than it affects, say, your skin or muscle cells. It’s a built-in selectivity that comes from how immune cells are wired.
What It Does to the Immune Response
By blocking T and B cell proliferation, CellCept suppresses both arms of your immune system. T cells are responsible for directly attacking foreign tissue (cellular immunity), while B cells produce antibodies that flag transplanted organs for destruction (humoral immunity). When both of these cell populations can’t multiply effectively, the immune system’s ability to mount a rejection response drops significantly.
This dual suppression is the reason CellCept is approved for preventing organ rejection in kidney, heart, and liver transplant recipients aged 3 months and older. It’s always used alongside other immunosuppressants rather than on its own. Outside of transplant medicine, doctors also prescribe it off-label for autoimmune conditions like lupus nephritis, where the immune system mistakenly attacks the kidneys. In clinical comparisons for childhood lupus nephritis, CellCept produced remission rates around 70%, comparable to older, harsher immunosuppressive treatments.
How Your Body Processes It
Once CellCept is absorbed, your digestive system rapidly converts it to MPA. After MPA does its work, your liver converts it into an inactive byproduct that your kidneys filter out. Nearly all of the drug leaves through urine: about 93% of an administered dose is recovered in urine, with roughly 6% exiting through stool. Less than 1% of the drug appears in urine in its active form, meaning your body is efficient at deactivating it before excretion.
One practical detail worth knowing: proton pump inhibitors (common heartburn medications like pantoprazole) can reduce how much CellCept your body actually absorbs. One study found that pantoprazole cut MPA exposure by 34%, which is a substantial drop that could make the drug less effective. If you take both, your transplant team will likely want to account for this interaction.
How It Compares to Older Options
Before CellCept became standard, azathioprine was the go-to immunosuppressant paired with other drugs after transplant. In head-to-head trials, CellCept showed a trend toward fewer episodes of clinical acute rejection, with one large study reporting a hazard ratio of 0.58, meaning roughly 42% fewer clinical rejection episodes, though the result narrowly missed statistical significance. Over four years of follow-up, long-term graft outcomes between the two drugs were similar. The practical takeaway is that CellCept appears at least as effective as azathioprine and possibly better at preventing early rejection episodes, which is why it has largely replaced the older drug in transplant protocols.
Common Side Effects
Because CellCept’s mechanism targets rapidly dividing cells, the side effects track with that biology. The cells lining your gut divide quickly, so digestive problems are the most frequent complaint. In clinical trials of kidney transplant patients taking the standard dose, diarrhea affected about 31% of people, nausea around 20%, and constipation roughly 23%. These rates climbed higher in heart and liver transplant patients, who typically take larger doses. More than half of liver transplant patients in trials reported nausea and diarrhea.
The other major category is blood cell counts. Since CellCept suppresses the proliferation of immune cells, it can push white blood cell counts too low. Leukopenia (low white blood cells) occurred in about 23% of kidney transplant patients and up to 46% of liver transplant patients. Anemia affected roughly a quarter of kidney transplant recipients and over 40% of heart and liver recipients. Severe drops in a specific type of white blood cell called neutrophils, which fight bacterial infections, occurred in 2% to 3.6% of patients depending on the type of transplant. Regular blood work is a standard part of being on this medication so these drops can be caught early.
Pregnancy Risk
CellCept carries a serious and well-documented risk during pregnancy. Exposure during the first trimester is associated with increased rates of pregnancy loss and congenital malformations. The risk is significant enough that the FDA requires a formal Risk Evaluation and Mitigation Strategy (REMS) program for all mycophenolate products. The program’s central goal is preventing unplanned pregnancies in anyone taking the drug. If you’re of reproductive age and prescribed CellCept, you’ll be counseled on effective contraception, and pregnancy testing is part of the monitoring protocol before and during treatment.